Department of Clinical Research, London School of Hygiene & Tropical Medicine, London, UK; Infectious Diseases Research Collaboration, Kampala, Uganda.
Infectious Diseases Research Collaboration, Kampala, Uganda.
Lancet. 2020 Apr 18;395(10232):1292-1303. doi: 10.1016/S0140-6736(20)30214-2.
Long-lasting insecticidal nets (LLINs) are the primary malaria prevention tool, but their effectiveness is threatened by pyrethroid resistance. We embedded a pragmatic cluster-randomised trial into Uganda's national LLIN campaign to compare conventional LLINs with those containing piperonyl butoxide (PBO), a synergist that can partially restore pyrethroid susceptibility in mosquito vectors.
104 health sub-districts, from 48 districts in Uganda, were randomly assigned to LLINs with PBO (PermaNet 3.0 and Olyset Plus) and conventional LLINs (PermaNet 2.0 and Olyset Net) by proportionate randomisation using an iterative process. At baseline 6, 12, and 18 months after LLIN distribution, cross-sectional surveys were done in 50 randomly selected households per cluster (5200 per survey); a subset of ten households per cluster (1040 per survey) were randomly selected for entomological surveys. The primary outcome was parasite prevalence by microscopy in children aged 2-10 years, assessed in the as-treated population at 6, 12, and 18 months. This trial is registered with ISRCTN, ISRCTN17516395.
LLINs were delivered to households from March 25, 2017, to March 18, 2018, 32 clusters were randomly assigned to PermaNet 3.0, 20 to Olyset Plus, 37 to PermaNet 2.0, and 15 to Olyset Net. In the as-treated analysis, three clusters were excluded because no dominant LLIN was received, and four clusters were reassigned, resulting in 49 PBO LLIN clusters (31 received PermaNet 3.0 and 18 received Olyset Plus) and 52 non-PBO LLIN clusters (39 received PermaNet 2.0 and 13 received Olyset Net). At 6 months, parasite prevalence was 11% (386/3614) in the PBO group compared with 15% (556/3844) in the non-PBO group (prevalence ratio [PR] adjusted for baseline values 0·74, 95% CI 0·62-0·87; p=0·0003). Parasite prevalence was similar at month 12 (11% vs 13%; PR 0·73, 95% CI 0·63-0·85; p=0·0001) and month 18 (12% vs 14%; PR 0·84, 95% CI 0·72-0·98; p=0·029).
In Uganda, where pyrethroid resistance is high, PBO LLINs reduced parasite prevalence more effectively than did conventional LLINs for up to 18 months. This study provides evidence needed to support WHO's final recommendation on use of PBO LLINs.
The Against Malaria Foundation, UK Department for International Development, Innovative Vector Control Consortium, and Bill and Melinda Gates Foundation.
长效杀虫蚊帐(LLINs)是预防疟疾的主要工具,但由于拟除虫菊酯类杀虫剂的抗药性,其效果受到威胁。我们将一项实用的群组随机试验嵌入乌干达国家 LLIN 运动中,以比较含有增效醚(PBO)的传统 LLIN 与不含增效醚的 LLIN,增效醚可部分恢复蚊虫媒介对拟除虫菊酯类杀虫剂的敏感性。
104 个卫生分区,来自乌干达 48 个区,采用迭代过程按比例随机分配到含有增效醚的 LLIN(PermaNet 3.0 和 Olyset Plus)和传统 LLIN(PermaNet 2.0 和 Olyset Net)中。在 LLIN 分发后的第 6、12 和 18 个月,每个群组(5200 人)随机选择 50 户家庭进行横断面调查;每个群组(1040 人)随机选择 10 户家庭进行昆虫学调查。主要结局是 2-10 岁儿童的寄生虫患病率,在治疗人群中于第 6、12 和 18 个月进行显微镜检查评估。该试验在 ISRCTN 注册,ISRCTN17516395。
2017 年 3 月 25 日至 2018 年 3 月 18 日,LLIN 分发给家庭,共有 32 个群组被随机分配到 PermaNet 3.0、20 个群组分配到 Olyset Plus、37 个群组分配到 PermaNet 2.0、15 个群组分配到 Olyset Net。在治疗人群分析中,由于没有收到主要的 LLIN,有三个群组被排除在外,有四个群组被重新分配,导致 49 个含有 PBO 的 LLIN 群组(31 个收到 PermaNet 3.0,18 个收到 Olyset Plus)和 52 个非 PBO LLIN 群组(39 个收到 PermaNet 2.0,13 个收到 Olyset Net)。在第 6 个月,含有 PBO 的群组中寄生虫患病率为 11%(386/3614),而不含 PBO 的群组中寄生虫患病率为 15%(556/3844)(调整基线值后的患病率比[PR] 0.74,95%CI 0.62-0.87;p=0.0003)。第 12 个月(11% vs 13%;PR 0.73,95%CI 0.63-0.85;p=0.0001)和第 18 个月(12% vs 14%;PR 0.84,95%CI 0.72-0.98;p=0.029)的寄生虫患病率相似。
在拟除虫菊酯类杀虫剂抗药性较高的乌干达,含有 PBO 的 LLIN 在长达 18 个月的时间内比传统的 LLIN 更有效地降低了寄生虫的患病率。本研究提供了支持世卫组织最终推荐使用 PBO LLIN 的证据。
对抗疟疾基金会、英国国际发展部、创新蚊虫控制联盟和比尔及梅琳达·盖茨基金会。